CD19 expression

Very interesting. What is the cytogenetic of this patients? t(8;21)? Sometimes,AML with t(8;21) express CD19. (@ultimate_crush_)

We only found MDS-related mutations by NGS with diploid karyotype at baseline & relapse. The immunophenotype is that of an AML at relapse, with aberrant CD19 expression (no other B-cell markers detected) (@SibaElHussein)

Finally getting to this elegant study https://t.co/n51OKhDD1C by @DrMattWit @iannisaifantis1 who identified NUDT21 as a regulator of CD19 expression in B-ALL. Upregulation in humans coincided with CD19 loss after CD19 CART and Blina. @NatImmunol #CART #leusm #lymsm #immunotherapy (@RShouval)

Locke - low CD19 expression and high expression of immunosuppression related genes correlates with worse outcome with Axi-cel in 2nd line DLBCL from Zuma7 trial. #lymsm #ESHlymphoma2022. (@graham74GC)

If we were so particular to look for perfection, no one would ever diagnose any dz. Of course there are variations and exceptions. Yes 2-3% of AML's express CD19 and it doesn't mean that the information that applies to 90+% is not worth paying attention to or post. (@Persian1010)

Lymphocytosis patient with following flow profile: Flow cytometric analysis shows that the cells express CD5, CD19, CD20, and CD23. CD79b and FMC7 are negative. CD10 and Bcl-6 are also negative. 1.CLL, 2 HCL 3 FL 4MCL 5 MZL? (@wangyub)

I am still confused with CD19 in myeloma. Myeloma cells should have lost CD19. CD19 expresses in normal plasma cells. Kymriah worked with AutoSCT though not sure if this is from HDM or HDM + CAR. https://t.co/5wlvVgJ28d (@HenrychihangFu1)

In the phase 1B trial, a novel anti-CD19 CAR-expressing PD-1/CD28 chimeric switch-receptor (CD19-PD-1/CD28-CAR) was generated that had superior capability of killing PD-L1+ B-cell lymphoma cells in LBCL. https://t.co/Dc118YN8V8 (@michaelwangmd)

#Tandem22 #leusm Domizi: decr ILZF1 assoc with decreased CD19 surface expression. ILZF1 knockdown led to decreased CD19 CART activation. (@hemedoc)

#ASH21 #leusm Domizi: Ikaros knockdown decreases CD19 expression. Ikaros effects not mediated by transcriptional control of CD19 but by control of mRNA splicing genes. (@hemedoc)

The study by Hakan Köksal from Norway showed a 2 gen CD37 CAR comparable efficacy with CD19 CAR in aggressive B-cell lymphoma xenograft model in controlling tumor growth. They can effectively eradicate B-cell lymphoma tumors when CD19 Ag expression is lost https://t.co/uQzmLIhOxw (@michaelwangmd)

Nice hemepath AML pearl. T(8;21) AML/core binding factor associated with aberrant CD19 expression. Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5 | Oncogene https://t.co/vpbiTD3dnY (@AaronGoodman33)